- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 29
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 29, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 29.
Number 5: At this week’s swearing-in ceremony for Alex Azar, the new Secretary of HHS, President Donald Trump promised that the price of prescription drugs will “come rocketing down” under Azar’s leadership.
Number 4: Celltrion, maker of the biosimilar infliximab product Inflectra, has received a new warning letter from the FDA.
Number 3: A new drug pricing forecast from the consulting company Vizient suggests that biosimilars have reached a tipping point in the US marketplace.
Number 2: The Biosimilars Council has filed an amicus brief in an ongoing case brought by Pfizer against Johnson & Johnson.
Number 1: SB3, a proposed trastuzumab biosimilar developed by Samsung Bioepis, demonstrated equivalence with Herceptin, according to a new study appearing in the Journal of Clinical Oncology.
Finally, last week, our e-newsletter asked whether the FDA should release information from Complete Response Letters. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
